At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 33 enrolled
Drug / intervention
Certolizumab pegoldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Open-Label Study to Evaluate the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis Using an Electrochemiluminescent Immuno-Assay
In Brief
A Phase 1 clinical trial evaluating Certolizumab pegol for Rheumatoid Arthritis. Completed, enrolled 33 participants across 14 sites.
Detailed Summary
The purpose of the study is to evaluate the pharmacokinetics and safety of certolizumab pegol in adults with active rheumatoid arthritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedFeb 2021
Enrollment StartFeb 2021
Primary CompletionJan 2022
Study CompletionJun 2022
TodayJul 2026
First PostedFeb 5, 2021
Enrollment StartFeb 11, 2021
Primary CompletionJan 24, 2022
Study CompletionJun 27, 2022
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 5.4 years ago
Interventions
Certolizumab pegoldrug
* Pharmaceutical form: Solution for injection * Route of administration: Subcutaneous Subjects will receive certolizumab pegol in a pre-specified sequence during the study.